Filing Flows › Zevra Therapeutics (ZVRA) › Free cash flow
Zevra Therapeutics (ZVRA) free cash flow by quarter
Zevra Therapeutics' free cash flow was $9.8M in Q3 2026 (third quarter 2026), -42% from Q2 2026. Over the last 4 quarters it ranged from $4.2M (Q3 2025) to $16.8M (Q2 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $9.8M | -42% | +136% |
| Q2 2026 | $16.8M | +175% | — |
| Q1 2026 | $6.1M | +47% | — |
| Q3 2025 | $4.2M | — | — |
Q3 2026 at a glance
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Zevra Therapeutics' free cash flow?
Zevra Therapeutics' free cash flow was $9.8M in Q3 2026 (third quarter 2026), -42% from Q2 2026.
How has Zevra Therapeutics' free cash flow changed?
Over the last 4 quarters it ranged from $4.2M (Q3 2025) to $16.8M (Q2 2026).